跳至主要内容
临床试验/NCT00573833
NCT00573833已完成不适用

A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2007年11月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
23
试验地点
1
主要终点
Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity

研究概览

简要总结

RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells.

PURPOSE: This clinical trial is studying the side effects and how well internal radiation therapy works in treating patients with prostate cancer.

详细描述

OBJECTIVES:

Primary

  • To assess the feasibility of high-dose rate (HDR) brachytherapy (without the use of external-beam radiotherapy) as definitive treatment for patients with intermediate-risk prostate cancer.
  • To assess acceptable toxicity, defined as treatment related toxicity (urinary and rectal), no worse than that seen by patients treated with conventional therapy (grade 3 urinary toxicity < 10% and grade 3 rectal toxicity < 10%).

Secondary

  • To achieve adequate dosimetric coverage of the prostate comparable to current standards.
  • To assess the effect of treatment on sexual function.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

HDR Brachytherapy

Experimental

9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days

干预措施: quality-of-life assessment (Procedure)

HDR Brachytherapy

Experimental

9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days

干预措施: brachytherapy (Radiation)

HDR Brachytherapy

Experimental

9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days

干预措施: questionnaire administration (Other)

结局指标

主要结局

Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity

时间窗: At scheduled 3 month intervals for one year

Feasibility will be defined as an acceptable level of severe toxicity (both acute and late effects), and adequate dosimetric coverage. Severe toxicity will be defined as \> or = grade 3 NCI CTC toxicity

Number of Patients With an Acceptable Level of Treatment Related Urinary and Rectal Toxicity as Defined at < Grade 3 CTC Toxicity

时间窗: Within 90 days of treatment (early toxicities) or after 90 days (late toxicities)

urinary and rectal toxicity-see the adverse event tables

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验